- Policy
- Boryung's Dukarb Plus is about to be commercialized
- by Lee, Tak-Sun Oct 5, 2021 05:58am
- It was found that commercialization of the high blood pressure combination drugs including Boryung's Fimasartan is imminent. If this product is approved, a total of four products will form treatment options in the hypertension treatment lineup leading to Kanarb-Kanarb Plus-Dukarb. Through this, it is expected that the diversity of patient
- Company
- “Dupixent, a trusted AD treatment without safety concerns"
- by Oct 5, 2021 05:58am
- The biologic agent ‘Dupixent (dupilumab)’ holds an 'unrivaled' position in the treatment of severe atopic dermatitis. In the AD treatment environment that had used immunotherapies that bring a high burden of side effects, the introduction of a safe and effective option has greatly improved the symptoms and quality of life in AD patients.
- Policy
- Rate of reimbursement expansions is falling?
- by Lee, Hye-Kyung Oct 5, 2021 05:56am
- To the criticism that the rate of reimbursement extensions for anticancer drugs have been falling, the Health Insurance Review and Assessment Service had pointed to the increased number of high-priced drugs that are being covered with the RSA system. HIRA had explained that the increased number of drugs covered through the RSA system sinc
- Policy
- Kymriah's fast track is needed
- by Kim, Jung-Ju Oct 5, 2021 05:56am
- Patient groups objected to the decision of the Cancer Drugs Benefit Appeal Committee on hold against Kymriah (Tisagenleclecel), which drew attention to insurance benefits as a cell therapy and a "one-shot treatment." This is because it is a new drug that is directly related to life for leukemia patients, and even though they have to be paid i
- Company
- All 15 pharmaceutical unions gathered together
- by An, Kyung-Jin Oct 5, 2021 05:56am
- A labor union composed of workers from 15 domestic pharmaceutical and bio companies has begun in earnest to integrate. According to the industry on the 29th, representatives of labor unions from 15 pharmaceutical and bio companies currently active in Korea gathered to form the National Pharmaceutical & Bio Labor Union (NPU) and began offic
- Company
- Liver cancer pioneer ‘Nexavar,' the star in its guidelines
- by Eo, Yun-Ho Oct 1, 2021 06:09am
- There are two reasons why new drug development is slow for a certain disease: its marketability is low or the development of the drug is difficult. When developed, new drugs developed in the latter situation attract more widespread attention. Liver cancer (hepatocellular carcinoma) is a typical example of this. And the only targete
- Company
- Only Taejoon’s succeeds in avoiding Simbrinza’s patent
- by Kim, Jin-Gu Oct 1, 2021 06:09am
- Taejoon Pharmaceutical succeeds in avoiding the patent for Novartis’s glaucoma treatment ‘Simbrinza eyedrops (brimonidine+ brinzolamide).’ Being the only company to successfully avoid Novartis’s patent, Taejoon Pharmaceutical will now be able to develop a generic version of Simbrinza Eye Drops in a relatively relaxed manner. Acco
- Product
- Smoking cessation tx, sold out due to impurities
- by Kim JiEun Oct 1, 2021 06:08am
- According to local pharmacies on the 1st, most Bupropions used for smoking cessation treatment are sold out or lack of inventory, making it difficult to order at online malls. This out of stock is related to the recent controversy over the detection of impurities in the Varenicline. As NNV, a carcinogen, was detected in Champix (Vareniclin
- Policy
- Botulinum toxin by fraudulent means can be revoked
- by Lee, Jeong-Hwan Oct 1, 2021 06:08am
- Regulations on handling and management, such as reporting high-risk pathogens such as botulinum toxin and anthrax, will be strengthened, and permission for bioterrorism infectious disease pathogens licensed by fraudulent methods will be revoked. On the 28th, Baek Jong-heon (Busan Geumjeong-gu), a member of the National Assembly's Health an
- Policy
- Domestic new drugs shouldn't be discriminated against
- by Lee, Jeong-Hwan Oct 1, 2021 06:08am
- Problems with the PVA system are expected to be discussed during this year's parliamentary audit of the National Assembly's Health and Welfare Committee. The domestic pharmaceutical community criticized that it is too harsh for the government to unilaterally decide on a drug price cut without acknowledging the innovation of new domestic drugs
